BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,942 | -19.7% | 616,154 | -3.8% | 0.06% | -10.4% |
| Q2 2023 | $52,260 | +9.0% | 640,207 | -0.9% | 0.07% | +4.7% |
| Q1 2023 | $47,926 | -11.2% | 645,988 | -0.8% | 0.06% | -13.5% |
| Q4 2022 | $53,995 | -99.9% | 651,488 | +335.9% | 0.07% | +21.3% |
| Q3 2022 | $42,451,000 | -18.5% | 149,474 | -0.5% | 0.06% | -10.3% |
| Q2 2022 | $52,093,000 | -30.6% | 150,281 | -13.3% | 0.07% | -15.0% |
| Q1 2022 | $75,065,000 | -15.5% | 173,344 | +0.9% | 0.08% | -10.1% |
| Q4 2021 | $88,840,000 | +5.4% | 171,724 | -1.3% | 0.09% | -1.1% |
| Q3 2021 | $84,290,000 | -25.2% | 173,949 | -30.4% | 0.09% | -22.4% |
| Q2 2021 | $112,612,000 | +10.6% | 250,104 | -6.2% | 0.12% | +2.7% |
| Q1 2021 | $101,787,000 | +10.5% | 266,506 | -8.1% | 0.11% | +9.7% |
| Q4 2020 | $92,110,000 | +25.4% | 290,066 | -2.2% | 0.10% | +14.4% |
| Q3 2020 | $73,444,000 | -8.7% | 296,466 | -2.7% | 0.09% | -12.6% |
| Q2 2020 | $80,441,000 | +33.2% | 304,621 | -4.4% | 0.10% | +13.2% |
| Q1 2020 | $60,389,000 | -13.8% | 318,476 | -0.3% | 0.09% | +9.6% |
| Q4 2019 | $70,085,000 | +9.0% | 319,280 | -2.8% | 0.08% | +2.5% |
| Q3 2019 | $64,283,000 | -10.8% | 328,530 | -4.9% | 0.08% | -10.0% |
| Q2 2019 | $72,035,000 | +3.0% | 345,510 | -1.9% | 0.09% | 0.0% |
| Q1 2019 | $69,921,000 | +37.5% | 352,156 | +0.3% | 0.09% | +21.6% |
| Q4 2018 | $50,834,000 | -35.6% | 351,256 | -9.1% | 0.07% | -20.4% |
| Q3 2018 | $78,885,000 | +38.2% | 386,481 | +0.2% | 0.09% | +31.0% |
| Q2 2018 | $57,091,000 | -5.4% | 385,881 | -3.4% | 0.07% | -5.3% |
| Q1 2018 | $60,338,000 | -1.1% | 399,481 | -15.1% | 0.08% | +2.7% |
| Q4 2017 | $60,984,000 | +7.1% | 470,739 | -0.0% | 0.07% | 0.0% |
| Q3 2017 | $56,932,000 | +1.6% | 470,939 | -1.2% | 0.07% | -1.4% |
| Q2 2017 | $56,017,000 | +16.3% | 476,739 | +0.6% | 0.07% | +13.8% |
| Q1 2017 | $48,176,000 | -7.1% | 473,940 | -6.0% | 0.06% | -11.0% |
| Q4 2016 | $51,831,000 | -6.1% | 504,042 | 0.0% | 0.07% | -8.8% |
| Q3 2016 | $55,193,000 | -3.5% | 504,042 | -0.6% | 0.08% | -3.6% |
| Q2 2016 | $57,202,000 | +11.9% | 507,242 | -6.2% | 0.08% | +6.4% |
| Q1 2016 | $51,101,000 | +23.9% | 540,636 | +17.9% | 0.08% | +23.8% |
| Q4 2015 | $41,255,000 | -2.7% | 458,386 | 0.0% | 0.06% | -6.0% |
| Q3 2015 | $42,382,000 | -6.0% | 458,386 | +0.1% | 0.07% | +1.5% |
| Q2 2015 | $45,088,000 | -0.5% | 457,887 | +1.4% | 0.07% | 0.0% |
| Q1 2015 | $45,307,000 | +6.6% | 451,757 | -1.7% | 0.07% | +4.8% |
| Q4 2014 | $42,482,000 | – | 459,757 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |